Business Context and Reporting Period
Company: Predictive Oncology Inc. (POAI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: The Company applies artificial intelligence (AI) to support oncology drug discovery using a proprietary biobank of 150,000+ tumor samples and 3D cell culture models. Following the disposal of its Eagan operating segment (STREAMWAY product line) in March 2025, the Company now operates as a single segment focused on AI-driven cancer therapy development. The former Birmingham and Eagan segments are reported as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Revenue (Continuing Ops) | $2,682 | $112,992 | $72,113 |
| Net Loss (Continuing Ops) | $(1,978,895) | $(4,264,311) | $(6,020,774) |
| Net Loss (Total) | $(2,070,462) | $(4,513,335) | $(7,400,104) |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.55) | $(1.70) |
| Cash and Cash Equivalents | $506,078 (as of June 30, 2025) | ||
| Operating Cash Flow (Continuing) | $(4,280,632) (Six Months 2025) | ||
| Total Current Liabilities | $3,845,439 (as of June 30, 2025) | ||
| Stockholders' Deficit | $(1,653,400) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue: Revenue from continuing operations decreased 96% in Q2 2025 ($2,682) compared to Q2 2024 ($67,255) due to decreased sales of 3D models. However, for the six-month period, revenue increased 57% ($112,992 vs. $72,113) driven by the completion of a specific 3D model project in 2025.
- Operating Expenses: Total operating expenses for the six months ended June 30, 2025, decreased by approximately $1.09 million compared to the prior year, primarily due to reduced headcount and consultant fees. General and Administrative (G&A) expenses decreased by $447,000, while Sales and Marketing expenses decreased by $470,000.
- Other Income: Other income increased significantly to $685,852 for the six months ended June 30, 2025, compared to $28,118 in the prior year. This was primarily due to a non-cash write-off of aged accounts payable and accrued expenses.
- Discontinued Operations: The Company recorded a loss from discontinued operations of $249,024 for the six months ended June 30, 2025, compared to a loss of $1.38 million in the prior year. This improvement reflects the cessation of operations and the sale of the Eagan business assets for $625,000.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The Company has substantial doubt about its ability to continue as a going concern within one year. It holds only $506,078 in cash against $3.85 million in current liabilities and an accumulated deficit of $184.9 million. Significant additional capital is required to sustain operations.
- Nasdaq Delisting Risk: The Company received notice of delisting from Nasdaq due to failure to meet the $2.5 million stockholders' equity requirement and the $1.00 minimum bid price requirement. A hearing was held in July 2025, and Nasdaq granted an extension until December 8, 2025, to demonstrate compliance. The Company is pursuing a 1-for-15 reverse stock split and a Standby Equity Purchase Agreement (SEPA) to regain compliance.
- Legal Contingency: Renovaro, Inc. filed a lawsuit in Delaware Chancery Court on May 8, 2025, alleging breach of a Letter of Intent (LOI) regarding a proposed merger that was terminated in March 2025. Renovaro seeks to compel the merger. The Company contests the lawsuit, but an adverse outcome could materially impact financial condition.
- Financing Activities: The Company raised capital through a Registered Direct Offering ($545k), a private placement ($300k), warrant exercises ($1.52M), and an At-The-Market (ATM) offering ($286k) during the first half of 2025. On July 1, 2025, the Company entered into a SEPA with Yorkville to sell up to $10 million of common stock.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $506,078 cash balance against the $3.85 million in current liabilities and the timeline for the next financing tranche.
- Nasdaq Compliance: Monitor the progress of the 1-for-15 reverse stock split and the execution of the SEPA to ensure compliance with the December 8, 2025, deadline.
- Legal Exposure: Assess the potential financial impact of the Renovaro lawsuit and the likelihood of a forced merger or significant settlement.
- Revenue Concentration: Note that substantially all revenue from continuing operations in the first half of 2025 was attributable to a single customer.
- Dilution Risk: Evaluate the potential dilution from the SEPA (up to $10 million), the reverse stock split, and ongoing ATM offerings required to maintain operations.